Recent Trends in Therapeutic Antibodies Development
Read WhitepaperOver the past few decades, monoclonal antibodies (mAbs) have revolutionized the world of medicine. With their remarkable potential as targeted drugs, they have become a powerful tool in molecular biology and game-changers in the pharmaceutical industry. In fact, nearly 20% of all drugs approved by the FDA are now mAbs,1 and the global antibody market is projected to reach $479 billion by 2028.2
Let’s TalkIn this whitepaper we outline the challenges associated with developing therapeutic antibodies and explore solutions for reducing development timelines and costs.
Get ready to:
- Delve into the fascinating history of mAbs, starting from the groundbreaking work of Georges J.F. Köhler and César Milstein, who pioneered the hybridoma method.
- Explore the development of the first therapeutic mAb and its subsequent impact on organ transplantation.
- Take a closer look at the pivotal discoveries made by James Allison and Tasuko Honjo, which led to the approval of immune checkpoint inhibitors for cancer therapy.
- Learn more about the challenges associated with developing therapeutic antibody products and get valuable insights into how development timelines and costs can be reduced.
Read Whitepaper
Let’s Talk
Automation platforms and precision instruments can streamline development—from early-stage research to analysis—helping to ensure a steady pipeline of therapeutic mAbs reach patients in need faster. Let’s talk about how we can help you overcome manual barriers, minimize downtime and reduce time to market.
Learn More
Our Team is Ready to Help
Let’s talk about how we can help you overcome manual barriers, minimize downtime and reduce time to market.
References
1. Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20:491-495. doi: 10.1038/d41573-021-00079-7
2. MarketsandMarkets. Antibody Therapeutics Market Size, Share, Trends and Revenue Forecast [Latest]. https://www.marketsandmarkets.com/Market-Reports/antibody-therapeutics-market-178852478.html. Published December 2023. Accessed March 7, 2024.
© 2000-2024 贝克曼库尔特国际贸易（上海）有限公司保留最终解释权
NOT ALL PRODUCTS ARE AVAILABLE IN ALL COUNTRIES.
PRODUCT AVAILABILITY AND REGULATORY STATUS DEPENDS ON COUNTRY REGISTRATION PER APPLICABLE REGULATIONS
The listed regulatory status for products correspond to one of the below:
IVD: In Vitro Diagnostic Products. These products are labeled "For In Vitro Diagnostic Use."
ASR: Analyte Specific Reagents. These reagents are labeled "Analyte Specific Reagents. Analytical and performance characteristics are not established."
CE: Products intended for in vitro diagnostic use and conforming to European Directive (98/79/EC). (Note: Devices may be CE marked to other directives than (98/79/EC)
RUO: Research Use Only. These products are labeled "For Research Use Only. Not for use in diagnostic procedures."
LUO: Laboratory Use Only. These products are labeled "For Laboratory Use Only."
No Regulatory Status: Non-Medical Device or non-regulated articles. Not for use in diagnostic or therapeutic procedures.
沪ICP备18036651号-1
沪公网安备 31010502004935号
互联网药品信息服务资格证书（沪）-非经营性-2020-0189
沪(浦)应急管危经许[2022]200234